The clinical trials targeting ITGB2 (NCT03812263), GAA (NCT00976352), and LCT (NCT02902016, NCT01145586, and NCT05100719) could be translated to PD in the future if found effective. The gene discussed is ITGB2; the disease is Parkinson disease.